Non-cutaneous syncytial myoepitheliomas are identical to cutaneous counterparts: a clinicopathologic study of 24 tumors occurring at diverse locations.
Cutaneous syncytial myoepithelioma
EWSR1 rearrangement
EWSR1::PBX3
Myoepithelioma
Syncytial myoepithelioma
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
15
06
2023
accepted:
21
07
2023
revised:
13
07
2023
medline:
27
11
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
ppublish
Résumé
Cutaneous syncytial myoepithelioma (CSM) is a rare myoepithelioma variant of skin, characterized by intradermal syncytial growth of spindle cells with a distinct immunophenotype of EMA and S100 positivity and infrequent keratin expression. While CSM was first described as a cutaneous tumor, singular non-cutaneous cases have since been reported in bone. We aimed to investigate the clinicopathological features of this variant across all anatomic sites through a large multi-institutional study. We complied a total of 24 myoepitheliomas with syncytial growth from our files. The tumors occurred in 12 male and 12 female patients (M:F = 1:1), with a median age of 31 years (range, 9-69 years). While the majority of tumors (75%, n = 18) occurred in skin, a significant subset (25%, n = 6) arose in non-cutaneous sites, including bone (n = 3), bronchus/trachea (n = 2), and interosseous membrane of tibia/fibula (n = 1). Tumor size ranged from 0.4 to 5.9 cm. Clinical follow-up (7 patients; range 14-202 months; median 56.5 months) showed a single local recurrence 8 years after incomplete skin excision but no metastases; all patients were alive at the time of last follow-up without evidence of disease. Histologically, all tumors were pink at low-power and characterized by a syncytial growth of bland ovoid, spindled, or histiocytoid cells with eosinophilic cytoplasm and prominent perivascular lymphoplasmacytic inflammation. One-third displayed adipocytic metaplasia (8/24). Rare cytologic atypia was seen but was not associated with increased mitotic activity. All tumors expressed S100, SMA, and/or EMA. Keratin expression was absent in most cases. Molecular analysis was performed in 16 cases, all showing EWSR1-rearrangments. In total, 15/15 (100%) harbored an EWSR1::PBX3 fusion, whereas 1 case EWSR1 FISH was the only molecular study performed. Syncytial myoepithelioma is a rare but recognizable morphologic variant of myoepithelioma which may have a predilection for skin but also occurs in diverse non-cutaneous sites. Our series provides evidence supporting a reappraisal of the term "cutaneous syncytial myoepithelioma," as 25% of patients in our series presented with non-cutaneous tumors; thus, we propose the term "syncytial myoepithelioma" to aid pathologist recognition and avoidance of potentially confusing terminology when referring to non-cutaneous examples. The behavior of syncytial myoepithelioma, whether it arises in cutaneous or non-cutaneous sites, is indolent and perhaps benign with a small capacity for local recurrence.
Identifiants
pubmed: 37548750
doi: 10.1007/s00428-023-03609-3
pii: 10.1007/s00428-023-03609-3
doi:
Substances chimiques
Biomarkers, Tumor
0
Keratins
68238-35-7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
665-675Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Jo VY, Antonescu CR, Zhang L, Dal Cin P, Hornick JL, Fletcher CDM (2013) Cutaneous syncytial myoepithelioma: clinicopathologic characterization in a series of 38 cases. Am J Surg Pathol 37:710–718
pubmed: 23588365
pmcid: 3628558
doi: 10.1097/PAS.0b013e3182772bba
Jo VY, Antonescu CR, Dickson BC, Swanson D, Zhang L, Fletcher CDM et al (2019) Cutaneous syncytial myoepithelioma is characterized by recurrent EWSR1-PBX3 fusions. Am J Surg Pathol 43:1349–1354
pubmed: 31135487
pmcid: 6742566
doi: 10.1097/PAS.0000000000001286
Lee JH, Huang HY, Lan J, Hwang CC, Liu CY (2015) Cutaneous syncytial myoepithelioma: a case report with emphasis on the differential diagnosis of problematic dermal tumors. Oncol Lett 9:2275–2277
pubmed: 26137055
pmcid: 4467334
doi: 10.3892/ol.2015.3055
Pizzi M, Facchin F, Kohlscheen E, Sartore L, Salmaso R, Bassetto F (2016) Cutaneous syncytial myoepithelioma: clinico-pathological features and differential diagnosis. Pathol Res Pract 212:954–956
pubmed: 27502466
doi: 10.1016/j.prp.2016.07.013
Alomari AK, Brown N, Andea AA, Betz BL, Patel RM (2017) Cutaneous syncytial myoepithelioma: a recently described neoplasm which may mimic nevoid melanoma and epithelioid sarcoma. J Cutan Pathol 44:892–897
pubmed: 28708250
pmcid: 5605446
doi: 10.1111/cup.13005
Wales C, Diamond S, Hinds B (2020) Cutaneous syncytial myoepithelioma: a nondescript skin tumor with serious diagnostic pitfalls. Int J Surg Pathol 28:63–67
pubmed: 31587595
doi: 10.1177/1066896919879755
Shimada K, Ansai O, Katsumi T, Deguchi T, Hayashi R, Yuki A et al (2022) A case of cutaneous syncytial myoepithelioma with extensive adipocytic metaplasia: usefulness of EWSR1-PBX3 gene fusion analysis. J Cutan Pathol 49:412–417
pubmed: 34854109
doi: 10.1111/cup.14179
MacKinnon WF, Carter MD, Bridge JA, Tremaine RD, Walsh NMG (2019) EWSR1-PBX3 gene fusion in cutaneous syncytial myoepithelioma. J Cutan Pathol 46:421–424
pubmed: 30834570
doi: 10.1111/cup.13450
Skalova A, Vanecek T, Martinek P, Weinreb I, Stevens TM, Simpson RHW et al (2018) Molecular profiling of mammary analog secretory carcinoma revealed a subset of tumors harboring a novel ETV6-RET translocation: report of 10 Cases. Am J Surg Pathol 42:234–246
pubmed: 29076873
doi: 10.1097/PAS.0000000000000972
Hornick JL, Fletcher CDM (2004) Cutaneous myoepithelioma: a clinicopathologic and immunohistochemical study of 14 cases. Hum Pathol 35:14–24
pubmed: 14745720
doi: 10.1016/j.humpath.2003.08.016
Agaram NP, Chen HW, Zhang L, Sung YS, Panicek D, Healey JH et al (2015) EWSR1-PBX3: a novel gene fusion in myoepithelial tumors. Genes, Chromosom Cancer 54:63–71
pubmed: 25231231
doi: 10.1002/gcc.22216
Suurmeijer AJH, Dickson BC, Swanson D, Zhang L, Sung YS, Fletcher CD, Antonescu CR (2020) A morphologic and molecular reappraisal of myoepithelial tumors of soft tissue, bone, and viscera with EWSR1 and FUS gene rearrangements. Genes Chromosom Cancer 59(6):348–356
pubmed: 31994243
doi: 10.1002/gcc.22835
Schnabel CA, Selleri L, Jacobs Y, Warnke R, Cleary ML (2001) Expression of Pbx1b during mammalian organogenesis. Mech Dev 100:131–135
pubmed: 11118899
doi: 10.1016/S0925-4773(00)00516-5
Laurent A, Bihan R, Omilli F, Deschamps S, Pellerin I (2008) PBX proteins: much more than Hox cofactors. Int J Dev Biol 52(1):9–20
pubmed: 18033668
doi: 10.1387/ijdb.072304al
Han HB, Gu J, Zuo HJ, Chen ZG, Zhao W, Li M et al (2012) Let-7c functions as a metastasis suppressor by targeting MMP11 and PBX3 in colorectal cancer. J Pathol 226(3):544–555
pubmed: 21984339
doi: 10.1002/path.3014
Ramberg H, Alshbib A, Berge V, Svindland A, Taskén KA (2011) Regulation of PBX3 expression by androgen and Let-7d in prostate cancer. Mol Cancer 10:50
pubmed: 21548940
pmcid: 3112428
doi: 10.1186/1476-4598-10-50
Li H, Sun G, Liu C, Wang J, Jing R, Wang J et al (2017) PBX3 is associated with proliferation and poor prognosis in patients with cervical cancer. Onco Targets Ther 10:5685–5694
pubmed: 29225475
pmcid: 5709993
doi: 10.2147/OTT.S150139
Li Y, Sun Z, Zhu Z, Zhang J, Sun X, Xu H (2014) PBX3 is overexpressed in gastric cancer and regulates cell proliferation. Tumour Biol 35(5):4363–4368
pubmed: 24375258
doi: 10.1007/s13277-013-1573-6
Li Z, Zhang Z, Li Y, Arnovitz S, Chen P, Huang H et al (2013) PBX3 is an important cofactor of HOXA9 in leukemogenesis. Blood 121:1422–1431
pubmed: 23264595
pmcid: 3578957
doi: 10.1182/blood-2012-07-442004
Panagopoulos I, Gorunova L, Bjerkehagen B, Heim S (2015) Fusion of the genes EWSR1 and PBX3 in retroperitoneal leiomyoma with t(9;22)(q33;q12). PLoS One 10:e012428
doi: 10.1371/journal.pone.0124288
Panagopoulos I, Gorunova L, Brunetti M, Agostini A, Andersen HK, Lobmaier I et al (2017) Genetic heterogeneity in leiomyomas of deep soft tissue. Oncotarget 8:48769–48781
pubmed: 28591699
pmcid: 5564723
doi: 10.18632/oncotarget.17953
Haglund C, Zemmler M, Tsagkozis P, Haglund de Flon F (2023) An intraosseous myoepithelial carcinoma with a EWSR1::PBX3 fusion. Genes Chromosom Cancer 2. https://doi.org/10.1002/gcc.2314
Hornick JL, Dal Cin P, Fletcher CDM (2009) Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. Am J Surg Pathol 33:542–550
pubmed: 19033866
doi: 10.1097/PAS.0b013e3181882c54
Jo VY, Fletcher CDM (2017) SMARCB1/INI1 Loss in epithelioid schwannoma: a clinicopathologic and immunohistochemical study of 65 cases. Am J Surg Pathol 41:1013–1022
pubmed: 28368924
doi: 10.1097/PAS.0000000000000849
Doyle LA, Fletcher CDM (2011) EMA positivity in epithelioid fibrous histiocytoma: a potential diagnostic pitfall. J Cutan Pathol 38:697–703
pubmed: 21752057
doi: 10.1111/j.1600-0560.2011.01747.x
Doyle LA, Mariño-Enriquez A, Fletcher CDM, Hornick JL (2015) ALK rearrangement and overexpression in epithelioid fibrous histiocytoma. Mod Pathol 28:904–912
pubmed: 25857825
doi: 10.1038/modpathol.2015.49
Agaram NP, Zhang L, Sung YS, Singer S, Stevens T, Prieto-Granada CN, Bishop JA, Wood BA, Swanson D, Dickson BC, Antonescu CR (2019) GLI1-amplifications expand the spectrum of soft tissue neoplasms defined by GLI1 gene fusions. Mod Pathol 32:1617–1626
pubmed: 31189998
pmcid: 6821565
doi: 10.1038/s41379-019-0293-x
Antonescu CR, Agaram NP, Sung YS, Zhang L, Swanson D, Dickson BC (2018) A distinct malignant epithelioid neoplasm with GLI1 gene rearrangements, frequent S100 protein expression, and metastatic potential: expanding the spectrum of pathologic entities with ACTB/MALAT1/PTCH1-GLI1 fusions. Am J Surg Pathol 42:553–560
pubmed: 29309307
pmcid: 5844813
doi: 10.1097/PAS.0000000000001010
Liu J, Mao R, Lao IW, Yu L, Bai Q, Zhou X, Wang J (2022) GLI1-altered mesenchymal tumor: a clinicopathological and molecular analysis of ten additional cases of an emerging entity. Virchows Arch 480:1087–1099
pubmed: 34779913
doi: 10.1007/s00428-021-03224-0
Cloutier JM, Charville GW, Mertens F, Sukov W, Fritchie K, Perry KD, Edgar M, Rowsey RA, Folpe AL (2021) “Inflammatory leiomyosarcoma” and “histiocyte-rich rhabdomyoblastic tumor”: a clinicopathological, immunohistochemical and genetic study of 13 cases, with a proposal for reclassification as “inflammatory rhabdomyoblastic tumor”. Mod Pathol 34:758–769
pubmed: 33318583
doi: 10.1038/s41379-020-00703-8
Hornick JL, Fletcher CD (2005) Soft tissue perineurioma: clinicopathologic analysis of 81 cases including those with atypical histologic features. Am J Surg Pathol 29:845–858
pubmed: 15958848
doi: 10.1097/01.pas.0000155166.86409.d2
Mariño-Enríquez A, Fletcher CD (2012) Angiofibroma of soft tissue: clinicopathologic characterization of a distinctive benign fibrovascular neoplasm in a series of 37 cases. Am J Surg Pathol 36(4):500–508
pubmed: 22301504
doi: 10.1097/PAS.0b013e31823defbe
Yamashita K, Baba S, Togashi Y, Dobashi A, Ae K, Matsumoto S, Tanaka M, Nakamura T, Takeuchi K (2023) Clinicopathologic and genetic characterization of angiofibroma of soft tissue: a study of 12 cases including two cases with AHRR::NCOA3 gene fusion. Histopathology 83:57–66
pubmed: 36860189
doi: 10.1111/his.14899
Agaimy A, Perret R, Demicco EG, Gross J, Liu YJ, Azmani R, Engelmann C, Schubart C, Seppet J, Stoehr R, Le Loarer F, Dickson BC (2023) GAB1::ABL1 fusions define a distinctive soft tissue neoplasm, with variable perineurial differentiation, and a predilection for children and young adults. Genes Chromosom Cancer 62:449–459
pubmed: 36744864
doi: 10.1002/gcc.23131
Rekhi B, Antonescu CR, Chen G (2022) Angiomatoid fibrous histiocytoma. In: WHO classification of tumors of soft tissue and bone, vol 3, 5th edn. International Agency for Research on Cancer, Lyons, pp 271–273
Cheah AL, Zou Y, Lanigan C, Billings SD, Rubin BP, Hornick JL, Goldblum JR (2019) ALK Expression in angiomatoid fibrous histiocytoma: a potential diagnostic pitfall. Am J Surg Pathol 43:93–101
pubmed: 29877921
doi: 10.1097/PAS.0000000000001103
Baumhoer D, Rogozhin D (2022) Non-ossifying fibroma. In: WHO classification of tumors of soft tissue and bone, 5th edn. International Agency for Research on Cancer, Lyons, pp 447–448
Diaz-Perez JA, Nielsen GP, Antonescu C, Taylor MS, Lozano-Calderon SA, Rosenberg AE (2019) EWSR1/FUS-NFATc2 rearranged round cell sarcoma: clinicopathological series of 4 cases and literature review. Hum Pathol 90:45–53
pubmed: 31078563
pmcid: 6714048
doi: 10.1016/j.humpath.2019.05.001
Sigel JE, Smith TA, Reith JD, Goldblum JR (2001) Immunohistochemical analysis of anaplastic lymphoma kinase expression in deep soft tissue calcifying fibrous pseudotumor: evidence of a late sclerosing stage of inflammatory myofibroblastic tumor? Ann Diagn Pathol 5:10–14
pubmed: 11172201
doi: 10.1053/adpa.2001.21474
Cook JR, Dehner LP, Collins MH, Ma Z, Morris SW, Coffin CM et al (2001) Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study. Am J Surg Pathol 25:1364–1371
pubmed: 11684952
doi: 10.1097/00000478-200111000-00003
Cools J, Wlodarska I, Somers R, Mentens N, Pedeutour F, Maes B et al (2002) Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosom Cancer 34:354–362
pubmed: 12112524
doi: 10.1002/gcc.10033
Coffin CM, Hornick JL, Fletcher CDM (2007) Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol 31:509–520
pubmed: 17414097
doi: 10.1097/01.pas.0000213393.57322.c7
Thway K, Nicholson AG, Lawson K, Gonzalez D, Rice A, Balzer B, Swansbury J, Min T, Thompson L, Adu-Poku K, Campbell A, Fisher C (2011) Primary pulmonary myxoid sarcoma with EWSR1-CREB1 fusion: a new tumor entity. Am J Surg Pathol 35:1722–1732
pubmed: 21997693
doi: 10.1097/PAS.0b013e318227e4d2
Enzinger FM, Harvey DA (1975) Spindle cell lipoma. Cancer 36:1852–1859
pubmed: 1192370
doi: 10.1002/1097-0142(197511)36:5<1852::AID-CNCR2820360542>3.0.CO;2-U
Mariño-Enriquez A, Nascimento AF, Ligon AH, Liang C, Fletcher CD (2017) Atypical spindle cell lipomatous tumor: clinicopathologic characterization of 232 cases demonstrating a morphologic spectrum. Am J Surg Pathol 41:234–244
pubmed: 27879515
doi: 10.1097/PAS.0000000000000770
Gross JM, Perret R, Coindre JM, Le Loarer F, Michal M, Michal M, Miettinen M, McCabe CE, Nair AA, Swanson AA, Thangaiah JJ, Torres-Mora J, Bonadio A, Voltaggio L, Epstein JI, Gupta S, Folpe AL, Schoolmeester JK (2023) Lipoblastoma-like tumor and fibrosarcoma-like lipomatous neoplasm represent the same entity: a clinicopathologic and molecular genetic study of 23 cases occurring in both men and women at diverse locations. Mod Pathol 36:100246. https://doi.org/10.1016/j.modpat.2023.100246
doi: 10.1016/j.modpat.2023.100246
pubmed: 37307874
Anderson WJ, Mariño-Enríquez A, Trpkov K, Hornick JL, Nucci MR, Dickson BC, Fletcher CDM (2023) Expanding the clinicopathologic and molecular spectrum of lipoblastoma-like tumor in a series of 28 cases. Mod Pathol 100252. https://doi.org/10.1016/j.modpat.2023.100252
Clay MR, Martinez AP, Weiss SW, Edgar MA (2015) MDM2 amplification in problematic lipomatous tumors: analysis of FISH testing criteria. Am J Surg Pathol 39:1433–1439
pubmed: 26146760
doi: 10.1097/PAS.0000000000000468